Praxis Precision Medicines

Praxis moves ahead despite phase 3 tremor trial futility finding

Weeks after Praxis CEO said the chances of futility were “less than 3%,” an interim analysis found the study is unlikely to meet its primary endpoint.

Nick Paul Taylor Feb 28, 2025 9:11am

brain amyloid alzheimers strings detailed web complicated thought

Praxis epilepsy drug reduces seizures in phase 2 trial

Sep 3, 2024 10:21am

graphic of the brain and the electrical signals that make it up

Praxis' epilepsy drug hits in phase 2, sparking stock rise

Mar 26, 2024 10:24am

Praxis share price halved by tremor fail but still plans phase 3

Mar 3, 2023 9:05am

Praxis ends year on high with $100M biobucks UCB deal

Dec 14, 2022 5:29am

Praxis acts fast as depression drug flunks late-phase test

Jun 6, 2022 9:40am